Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy

Timothy M. Cox, Guillermo Drelichman, Renata Cravo, Manisha Balwani, Thomas Andrew Burrow, Ana Maria Martins, Elena Lukina, Barry Rosenbloom, Ozlem Goker-Alpan, Nora Watman, Amal El-Beshlawy, Priya S. Kishnani, Maria Lucia Pedroso, Sebastiaan J. M. Gaemers, Regina Tayag, M. Judith Peterschmitt

Blood (2017) 129 (17): 2375–2383.

https://doi.org/10.1182/blood-2016-12-758409

Published: 2017

Journal Articles

Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry

Pramod Mistry, MD PhD FRCP, Neal J. Weinreb, MD FACP, Julie Batista, ScM, ScD, Hans C. Andersson, MD, Manisha Balwani, MD MS, Thomas Andrew Burrow, MD, Joel Charrow, MD, Paige Kaplan, MB, BCh, Aneal Khan, MD MSc, FCCMG, FRCPC, Priya S. Kishnani, MD MB BS, Edwin H. Kolodny, MD, Barry E. Rosenbloom, MD, C. Ronald Scott, MD

Blood (2016) 128 (22): 4877.

https://doi.org/10.1182/blood.V128.22.4877.4877

Published: 2016

Journal Articles

Neutropenia In Glycogen Storage Disease 1b (GSD1b)

David C. Dale, MD, Audrey Anna Bolyard, RN, BS, Tracy M. Marrero, Merideth L. Kelley, MS, BS, Lan Phan, BA, Laurence A. Boxer, MD, Priya S. Kishnani, MD, MB, Joanne Kurtzberg, MD, David A. Weinstein, MD, MMSc

Blood (2013) 122 (21): 2265.

https://doi.org/10.1182/blood.V122.21.2265.2265

Published: 2013

Journal Articles

Neutropenia in Glycogen Storage Disease 1b (GSD1b)

David C. Dale, MD, Audrey Anna Bolyard, RN, BS, Tracy M. Marrero, Lan Phan, BA, Laurence A. Boxer, MD, Priya S. Kishnani, Joanne Kurtzberg, MD, David A. Weinstein

Blood (2011) 118 (21): 4791.

https://doi.org/10.1182/blood.V118.21.4791.4791

Published: 2011

Journal Articles

A Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in the Maintenance Therapy of Patients with Type 1 Gaucher Disease

Priya S Kishnani, MD

Blood (2008) 112 (11): 1271.

https://doi.org/10.1182/blood.V112.11.1271.1271

Published: 2008

NARROW

Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy

Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry

Neutropenia In Glycogen Storage Disease 1b (GSD1b)

Neutropenia in Glycogen Storage Disease 1b (GSD1b)

A Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in the Maintenance Therapy of Patients with Type 1 Gaucher Disease

Email alerts

ASH Publications

American Society of Hematology

Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy

Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry

Neutropenia In Glycogen Storage Disease 1b (GSD1b)

Neutropenia in Glycogen Storage Disease 1b (GSD1b)

A Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in the Maintenance Therapy of Patients with Type 1 Gaucher Disease

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only